Unicycive Therapeutics, Inc. (UNCY)
| Market Cap | 204.79M +162.1% |
| Revenue (ttm) | n/a |
| Net Income | -39.95M |
| EPS | -2.11 |
| Shares Out | 26.70M |
| PE Ratio | n/a |
| Forward PE | 1.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 496,924 |
| Open | 7.88 |
| Previous Close | 7.73 |
| Day's Range | 7.62 - 7.97 |
| 52-Week Range | 3.71 - 11.00 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 40.99 (+434.42%) |
| Earnings Date | May 12, 2026 |
About UNCY
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney inj... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for UNCY stock is "Strong Buy." The 12-month stock price target is $40.99, which is an increase of 434.42% from the latest price.
News
Unicycive Therapeutics price target lowered to $37 from $40 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $37 from $40 and keeps a Buy rating on the shares. The firm trimmed its target,…
Unicycive Therapeutics reports Q1 EPS (50c), consensus (47c)
“As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,” said…
Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update
MOUNTAIN VIEW, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today...
Unicycive Therapeutics initiated with a Buy at B. Riley
B. Riley initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $22 price target The firm says the investment thesis focuses on oxylanthanum carbonate, the company’s next generation...
Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
LOS ALTOS, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Co...
Unicycive Therapeutics price target lowered to $15 from $21 at Benchmark
Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $21 and keeps a Speculative Buy rating on the shares. After having updated the firm’s share count…
Unicycive Therapeutics price target lowered to $40 from $46 at Guggenheim
Guggenheim lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $40 from $46 and keeps a Buy rating on the shares. The firm made “relatively modest adjustments” to its…
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today a...
Unicycive Therapeutics management to meet with Piper Sandler
Meeting to be held in New York on February 25 hosted by Piper Sandler.
Unicycive Therapeutics initiated with a Buy at WestPark Capital
WestPark Capital initiated coverage of Unicycive Therapeutics (UNCY) with a Buy rating and $72 price target Given the view that a significant number of dialysis organizations are likely to switch…
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - February 17, 2026) - WHAT IS HAPPENING? Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY)...
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit
LOS ALTOS, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
FDA assigns Prescription Drug User Fee Act (PDUFA) target date of June 29, 2026 Ended 2025 with unaudited cash position of $41.3M with expected runway into 2027 LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE...
Unicycive Therapeutics announces FDA acceptance of OLC NDA resubmission
Unicycive Therapeutics (UNCY) announced that the U.S. Food and Drug Administration, FDA, has accepted the resubmission of its New Drug Application, NDA, for oxylanthanum carbonate, OLC, the Company’s ...
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
LOS ALTOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patient...
Unicycive Therapeutics resubmits NDA for oxylanthanum carbonate
Unicycive Therapeutics (UNCY) resubmitted its 505(b)(2) New Drug Application to the U.S. Food and Drug Administration for oxylanthanum carbonate, the Company’s investigational oral phosphate binder fo...
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission New PDUFA date expected in 1H 2026 within 30 days of NDA resubmission
Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf
Philadelphia, Pennsylvania--(Newsfile Corp. - December 1, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The investigation ...
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
LOS ALTOS, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
Unicycive Therapeutics reports Q3 EPS (46c), consensus (53c)
“With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the end of the year, following positive discussions with the FDA and our…
Unicycive Therapeutics sees cash runway into 2027
As of September 30, 2025, cash and cash equivalents totaled $42.7 million. The Company believes that it has a cash runway into 2027.
Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
- Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonst...
Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
LOS ALTOS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Com...
Unicycive Therapeutics to present new OLC data at ASN Kidney Week 2025
Unicycive Therapeutics (UNCY) announced that it will present new oxylanthanum carbonate, OLC, data at the American Society of Nephrology, ASN, Kidney Week 2025, which will take place in Houston, TX,…
Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference
Analysis of the data from the open-label pivotal trial of oxylanthanum carbonate (OLC) highlights that pill burden was significantly reduced in terms of both pill volume (7x) and pill count (2x) from ...